We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing
Read MoreHide Full Article
Key Takeaways
BridgeBio's infigratinib filing won FDA priority review, with a decision expected by Feb. 4, 2027.
Infigratinib targets FGFR3 directly and delivered 2.1 cm/year greater height growth than placebo.
BBIO-418 and encaleret could join infigratinib to diversify BridgeBio's revenue beyond Attruby.
BridgeBio Pharma (BBIO - Free Report) announced that the FDA accepted its regulatory filing seeking approval for the investigational oral drug infigratinib to treat children with achondroplasia, the most common form of dwarfism.
The agency has granted the filing priority review, under which the FDA aims to take action within six months instead of the standard 10 months. A final decision is expected by Feb. 4, 2027.
If approved, infigratinib could become the first approved oral therapy for achondroplasia. The drug takes a different approach from existing treatments, such as BioMarin Pharmaceutical’s (BMRN - Free Report) Voxzogo and Ascendis Pharma’s (ASND - Free Report) Yuviwel, which are administered by injection.
In achondroplasia, an overactive FGFR3 protein acts as a brake on bone growth. Infigratinib is designed to directly inhibit FGFR3, while Voxzogo and Yuviwel mimic CNP, a natural molecule that helps counteract FGFR3’s growth-suppressing signal and promote bone growth.
The filing is supported by data from the phase III PROPEL 3 study, which met its primary and key secondary endpoints. Study participants who received infigratinib for 52 weeks had a height growth rate that was 2.1 centimeters per year higher, on average, than those who received placebo.
BridgeBio intends to submit a similar regulatory filing for infigratinib in the EU before this year’s end, based on the PROPEL 3 results.
BBIO Stock’s Price Performance
Year to date, the company’s shares have lost 12% against the industry’s 7% growth.
Image Source: Zacks Investment Research
BridgeBio Eyes Multiple New Revenue Opportunities
The FDA's acceptance of infigratinib marks another regulatory milestone for BridgeBio as it continues to expand its product portfolio beyond Attruby, which is currently its only marketed product. The drug is approved for the treatment of adults with transthyretin amyloid cardiomyopathy (ATTR-CM).
However, the company has several regulatory catalysts over the next several months that could significantly diversify its revenue base. Infigratinib is one of three near-term commercialization opportunities, alongside BBP-418 and encaleret.
A filing for BBP-418 is already under FDA review for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), with a final decision expected by Nov. 27, 2026. A second regulatory filing for encaleret is also under review, seeking approval for a rare genetic endocrine disorder called autosomal dominant hypocalcemia type 1 (ADH1). A final decision is expected by May 8, 2027.
Together with infigratinib, BBP-418 and encaleret could significantly diversify BridgeBio's revenue base. If approved, these candidates would transform the company from a single-product business into a diversified rare disease commercial player, reducing its dependence on Attruby as its primary growth driver.
View the Zacks #1 Rank List
Image: Bigstock
FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing
Key Takeaways
BridgeBio Pharma (BBIO - Free Report) announced that the FDA accepted its regulatory filing seeking approval for the investigational oral drug infigratinib to treat children with achondroplasia, the most common form of dwarfism.
The agency has granted the filing priority review, under which the FDA aims to take action within six months instead of the standard 10 months. A final decision is expected by Feb. 4, 2027.
If approved, infigratinib could become the first approved oral therapy for achondroplasia. The drug takes a different approach from existing treatments, such as BioMarin Pharmaceutical’s (BMRN - Free Report) Voxzogo and Ascendis Pharma’s (ASND - Free Report) Yuviwel, which are administered by injection.
In achondroplasia, an overactive FGFR3 protein acts as a brake on bone growth. Infigratinib is designed to directly inhibit FGFR3, while Voxzogo and Yuviwel mimic CNP, a natural molecule that helps counteract FGFR3’s growth-suppressing signal and promote bone growth.
The filing is supported by data from the phase III PROPEL 3 study, which met its primary and key secondary endpoints. Study participants who received infigratinib for 52 weeks had a height growth rate that was 2.1 centimeters per year higher, on average, than those who received placebo.
BridgeBio intends to submit a similar regulatory filing for infigratinib in the EU before this year’s end, based on the PROPEL 3 results.
BBIO Stock’s Price Performance
Year to date, the company’s shares have lost 12% against the industry’s 7% growth.
Image Source: Zacks Investment Research
BridgeBio Eyes Multiple New Revenue Opportunities
The FDA's acceptance of infigratinib marks another regulatory milestone for BridgeBio as it continues to expand its product portfolio beyond Attruby, which is currently its only marketed product. The drug is approved for the treatment of adults with transthyretin amyloid cardiomyopathy (ATTR-CM).
However, the company has several regulatory catalysts over the next several months that could significantly diversify its revenue base. Infigratinib is one of three near-term commercialization opportunities, alongside BBP-418 and encaleret.
A filing for BBP-418 is already under FDA review for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), with a final decision expected by Nov. 27, 2026. A second regulatory filing for encaleret is also under review, seeking approval for a rare genetic endocrine disorder called autosomal dominant hypocalcemia type 1 (ADH1). A final decision is expected by May 8, 2027.
Together with infigratinib, BBP-418 and encaleret could significantly diversify BridgeBio's revenue base. If approved, these candidates would transform the company from a single-product business into a diversified rare disease commercial player, reducing its dependence on Attruby as its primary growth driver.
BridgeBio Pharma, Inc. Price
BridgeBio Pharma, Inc. price | BridgeBio Pharma, Inc. Quote
BBIO’s Zacks Rank
BridgeBio currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.